Novel Preclinical Drug Could Have Potential to Combat Depression, Brain Injury, and Cognitive Disorders

A preclinical drug that inhibits the kinase enzyme Cdk5 may have the potential to treat depression, brain injuries, and disorders associated with cognitive impairment.